An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.

PHASE3CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

November 30, 2017

Primary Completion Date

January 24, 2020

Study Completion Date

September 7, 2022

Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
DRUG

Palovarotene

Palovarotene was taken orally once daily at approximately the same time each day following a meal.

Trial Locations (16)

2065

Royal North Shore Hospital, Saint Leonards

4102

Queensland University of Technology, Woolloongabba

16147

Istituto Giannina Gaslini, Genoa

19104

Children's Hospital of Philadelphia, Philadelphia

University of Pennsylvania, Internal Medicine, Philadelphia

46026

Hospital Universitari i Politècnic La Fe, Unidad de Reumatología Pediatrica, Valencia

55905

Mayo Clinic, Rochester

75015

Groupe Hospitalier Necker Enfants Malades, Paris

94143

University of California San Francisco, Division of Endocrinology and Metabolism, San Francisco

C1199ACH

Hospital Italiano de Buenos Aires, Tte General Juan Domingo Peron 4190, Buenos Aires

05652-900

Hospital Israelita Albert Einstein, São Paulo

M5G 1X8

Hospital for Sick Children, 555 University Avenue, Toronto

M5G 2C4

Toronto General Hospital, Toronto

113-8655

The University of Tokyo Hospital, Tokyo

SE-90185

Norrlands Universitetssjukhus, Umeå

HA7 4LP

Royal National Orthopaedic Hospital, Brockely Hill, Stanmore

Sponsors
All Listed Sponsors
lead

Clementia Pharmaceuticals Inc.

INDUSTRY